AnaptysBio (NASDAQ:ANAB) Sets New 12-Month High on Analyst Upgrade

AnaptysBio, Inc. (NASDAQ:ANAB)’s share price hit a new 52-week high during trading on Wednesday after Barclays raised their price target on the stock from $78.00 to $79.00. Barclays currently has an overweight rating on the stock. AnaptysBio traded as high as $58.50 and last traded at $58.47, with a volume of 202416 shares traded. The stock had previously closed at $52.83.

A number of other equities research analysts have also commented on the company. Wall Street Zen lowered AnaptysBio from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 23rd. Truist Financial increased their price target on shares of AnaptysBio from $20.00 to $36.00 and gave the stock a “hold” rating in a research report on Monday, November 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AnaptysBio in a research report on Wednesday, January 21st. Wedbush reiterated an “outperform” rating and issued a $50.00 price objective on shares of AnaptysBio in a research note on Monday, November 24th. Finally, HC Wainwright lifted their target price on shares of AnaptysBio from $51.00 to $66.00 and gave the company a “buy” rating in a research note on Wednesday. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $68.67.

Insider Transactions at AnaptysBio

In other news, insider Eric J. Loumeau sold 10,000 shares of the company’s stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $54.00, for a total transaction of $540,000.00. Following the completion of the sale, the insider owned 12,835 shares in the company, valued at approximately $693,090. This represents a 43.79% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Daniel Faga sold 14,281 shares of the firm’s stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $44.71, for a total value of $638,503.51. Following the completion of the transaction, the chief executive officer directly owned 479,344 shares in the company, valued at $21,431,470.24. The trade was a 2.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 156,280 shares of company stock valued at $7,254,939 in the last three months. 33.50% of the stock is currently owned by company insiders.

More AnaptysBio News

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: Q4 results beat expectations — AnaptysBio reported $1.58 EPS vs. consensus $0.89 and revenue of $108.3M vs. $87.1M, signaling stronger-than-expected commercial/royalty receipts and driving confidence in near-term cash flow. ANAB Q4 Earnings Beat
• Positive Sentiment: Spin-off confirmed and on track — Management reiterated plans to separate the biopharma portfolio into a public company, First Tracks Biotherapeutics, targeted for Q2 2026 (possibly late‑April). Investors often reward separations that isolate distinct asset value. Spin-off Announcement
• Positive Sentiment: Business update highlights royalty upside and solid liquidity — Company noted ongoing Phase 1b activity for ANB033, strong GSK Jemperli sales growth (implying meaningful future royalties), and year‑end cash & investments of ~ $311M—supporting operations through the separation. Corporate Update & Financials
• Positive Sentiment: Analyst upgrades/price-target increases — Barclays raised its target to $79 with an overweight rating, and H.C. Wainwright raised its target to $66 (buy). These upgrades increase the visible upside and can attract buyers. Barclays PT Raise H.C. Wainwright PT Raise
• Neutral Sentiment: Short-interest notices appear to be data anomalies — filings/data feeds flagged a “large increase” but report zero shares and NaN changes; the published days-to-cover is 0.0. This looks like a reporting error rather than informative short‑activity. (Monitor for corrected filings.)
• Negative Sentiment: Underlying profitability metrics still negative — despite the quarter’s beat, the company reports a negative net margin and abnormal return-on-equity figures; some analysts still model a negative full‑year EPS, which leaves operating risk if royalty growth or the spin‑off timing disappoints.

Hedge Funds Weigh In On AnaptysBio

A number of institutional investors have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd boosted its holdings in shares of AnaptysBio by 940.8% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,530 shares of the biotechnology company’s stock worth $74,000 after buying an additional 1,383 shares during the period. Invesco Ltd. raised its holdings in AnaptysBio by 192.6% in the 4th quarter. Invesco Ltd. now owns 124,006 shares of the biotechnology company’s stock worth $6,012,000 after acquiring an additional 81,625 shares during the period. Mackenzie Financial Corp acquired a new position in AnaptysBio during the 4th quarter worth $1,166,000. XTX Topco Ltd boosted its holdings in AnaptysBio by 113.3% during the fourth quarter. XTX Topco Ltd now owns 38,637 shares of the biotechnology company’s stock valued at $1,873,000 after acquiring an additional 20,526 shares during the period. Finally, nVerses Capital LLC acquired a new stake in shares of AnaptysBio in the fourth quarter valued at about $215,000.

AnaptysBio Stock Up 14.6%

The company has a 50-day moving average price of $50.02 and a 200-day moving average price of $38.65. The company has a market capitalization of $1.68 billion, a price-to-earnings ratio of -116.44 and a beta of 0.32.

AnaptysBio (NASDAQ:ANAB) last announced its earnings results on Monday, March 9th. The biotechnology company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $0.89 by $0.69. The firm had revenue of $108.25 million during the quarter, compared to the consensus estimate of $87.09 million. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 5.64%. Equities analysts expect that AnaptysBio, Inc. will post -6.08 EPS for the current fiscal year.

AnaptysBio announced that its Board of Directors has initiated a stock repurchase program on Friday, November 21st that authorizes the company to repurchase $100.00 million in outstanding shares. This repurchase authorization authorizes the biotechnology company to buy up to 9.6% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s management believes its stock is undervalued.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.